Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE II TRIAL ADDRESSING FEASIBILITY AND ACTIVITY OF CLARITHROMYCIN + LENALIDOMIDE COMBINATION: A FULL ORAL TREATMENT FOR PATIENTS WITH RELAPSED/REFRACTORY MUCOSA-ASSOCIATED LYMPHOID TISSUE (MALT) LYMPHOMA

Next Previous
X
Search
Trial Profile

A PHASE II TRIAL ADDRESSING FEASIBILITY AND ACTIVITY OF CLARITHROMYCIN + LENALIDOMIDE COMBINATION: A FULL ORAL TREATMENT FOR PATIENTS WITH RELAPSED/REFRACTORY MUCOSA-ASSOCIATED LYMPHOID TISSUE (MALT) LYMPHOMA

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Clarithromycin (Primary) ; Lenalidomide (Primary)
  • Indications Marginal zone B-cell lymphoma
  • Focus Therapeutic Use
  • Acronyms CLEO

    • Most Recent Events

    • 04 Jun 2021 Planned End Date changed from 1 Feb 2030 to 1 Nov 2029.
    • 21 Jun 2020 Primary endpoint has not been met. (Tumor response assessment), according to results presented at the 25th Congress of the European Haematology Association.
    • 21 Jun 2020 Results presented at the 25th Congress of the European Haematology Association

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top